kawasaki disease and immunizations

  1. kawasaki disease def
    acute systemic vasculitis of unknown origin, assoc w spring cleaning
  2. prevalence of kawa
    infants and young children (18mo-5 yrs is pk incidence)
  3. etiology of kawa
    • season-more common in winter or spring
    • possible infectious cause
    • race-originally found in asian pts but affects all
  4. clinical pres of kawa
    • fever, bilateral nonexudative conjunctivitis
    • erythema of lips and oral mucosa
    • changes in extremities
    • rash-usually on extre
    • cervical lyphadenopathy
  5. classical diag of kawa
    • fever for five or more days
    • four or more of the following (5):
    • changes in extrem
    • rash-skin peels off
    • conjunc
    • cracking of lips and oral cavity, strawberry tongue
    • cervical lymphadenopathy
  6. goals of acute tx of kawa
    • reducing inflamm of coronary artery wall
    • preventing coronary thrombosis
  7. goals of management long termkawa
    preventing myocardial ischemia and infarction in those that develop aneurysms, tx all w possible diag
  8. pharmacotherapy for kawa
    • IVIG-2gm/kg in a single inf(fever should come down rapidly)
    • asa-80-100mg/kg/d in 4 doses during acute , dec to 3-5 mg/kg/d until follow up shows no coronary artery changes at 6-8 wks after onset of illness
  9. complications of kawa
    coronary artery aneurysms primarily in untreated children
  10. Part A-national vaccine injury compensation Act
    provides details related to compensaion if injury occurs
  11. part B
    removes manufactureres from liability if injuries occur as long as full info regatding product is provided
  12. part C
    FDA must be notified within 7 days if an adverse rxn does occur
  13. documentation of vaccines
    manufacturer, lot, date of admin, name, address, title of person giving
Card Set
kawasaki disease and immunizations